CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC) – the SHELTER Study
DOI 10.1055/s-0030-1263872
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Bitzer, M Horger, M Ebert, T Ganten, M Wörns, B Hauns, A Mais, R Jankowsky, B Hentsch, UM Lauer
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Resminostat (4SC-201) is a novel specific pan-HDAC inhibitor under clinical evaluation as mono or combination therapy for solid and hematological malignancies. Here, we describe the first results of a phase II study being started in 2009 to evaluate the safety, tolerability and efficacy of resminostat in patients with HCC exhibiting progressive disease under sorafenib first-line therapy. Methods: Patients with…
Zitieren
Zitierempfehlung
M Bitzer, M Horger, M Ebert, T Ganten, M Wörns, B Hauns, A Mais, R Jankowsky, B Hentsch, UM Lauer (2010) First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC) – the SHELTER Study. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0030-1263872
Mit CareLit weiterarbeiten